Literature DB >> 9862406

Haloperidol, raclopride, and eticlopride induce microcatalepsy during operant performance in rats, but clozapine and SCH 23390 do not.

S C Fowler1, J R Liou.   

Abstract

The purpose of this work was (1) to assess the ability of selected antipsychotic and comparison drugs to induce arrest of movement phenomena during operant responding and (2) to evaluate the capacity of muscarinic anitcholinergics to block such effects. The effects of haloperidol (0.02-0.12 mg/kg, i.p., 45 min), raclopride (0.05-0.80 mg/kg, i.p., 30 min) eticlopride (0.02-0.16 mg/kg, i.p., 45 min), clozapine (1.0-8.0 mg/kg, i.p., 60 min) and SCH 23390 (0.01-0.16 mg/kg, i.p., 30 min) were administered to rats for 4 weeks in a between-groups dosing design. Operant responses in 15 min and the maximum duration of the rat's muzzle entry into the reinforcement dipper well (the measure of arrest of movement that reflected microcatalepsy) were the quantitative measures of behavior. The D2 antagonists dose-relatedly decreased operant responding and increased maximum muzzle duration, effects that were significantly reversed by the anticholinergic scopolamine (0.1 mg/kg) or atropine (6.0 mg/kg). Although the atypical antipsychotic drug clozapine and the selective D1 antagonist SCH 23390 both significantly reduced operant responding, these drugs did not produce microcatalepsy. The results suggested that microcatalepsy expressed in the context of ongoing operant behavior may model low-dose extrapyramidal side effects.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9862406     DOI: 10.1007/s002130050742

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  15 in total

1.  Effects of cortical and striatal dopamine D1 receptor blockade on cued versus noncued behavioral responses.

Authors:  Won Yung Choi; Cecile Morvan Campbell; Peter D Balsam; Jon C Horvitz
Journal:  Behav Neurosci       Date:  2011-10       Impact factor: 1.912

Review 2.  Regional differences in the action of antipsychotic drugs: implications for cognitive effects in schizophrenic patients.

Authors:  Richard J Beninger; Tyson W Baker; Matthew M Florczynski; Tomek J Banasikowski
Journal:  Neurotox Res       Date:  2010-04-08       Impact factor: 3.911

3.  Kinetics modeling and occupancy studies of a novel C-11 PET tracer for VAChT in nonhuman primates.

Authors:  Hongjun Jin; Xiang Zhang; Xuyi Yue; Hui Liu; Junfeng Li; Hao Yang; Hubert Flores; Yi Su; Stanley M Parsons; Joel S Perlmutter; Zhude Tu
Journal:  Nucl Med Biol       Date:  2015-11-07       Impact factor: 2.408

4.  Evidence for the sensitivity of operant timing behaviour to stimulation of D1 dopamine receptors.

Authors:  T H C Cheung; G Bezzina; C L Hampson; S Body; K C F Fone; C M Bradshaw; E Szabadi
Journal:  Psychopharmacology (Berl)       Date:  2007-08-01       Impact factor: 4.530

5.  The adenosine A2A antagonist MSX-3 reverses the effort-related effects of dopamine blockade: differential interaction with D1 and D2 family antagonists.

Authors:  Lila T Worden; Mona Shahriari; Andrew M Farrar; Kelly S Sink; Jörg Hockemeyer; Christa E Müller; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2008-12-02       Impact factor: 4.530

Review 6.  A review of the discovery, pharmacological characterization, and behavioral effects of the dopamine D2-like receptor antagonist eticlopride.

Authors:  Jennifer L Martelle; Michael A Nader
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

7.  Examination of clozapine and haloperidol in improving ketamine-induced deficits in an incremental repeated acquisition procedure in BALB/c mice.

Authors:  Andrew Nathanael Shen; M Christopher Newland
Journal:  Psychopharmacology (Berl)       Date:  2015-10-29       Impact factor: 4.530

8.  Detailed analysis of food-reinforced operant lever pressing distinguishes effects of a cannabinoid CB1 inverse agonist and dopamine D1 and D2 antagonists.

Authors:  P J McLaughlin; K M Winston; L A Swezey; V K Vemuri; A Makriyannis; J D Salamone
Journal:  Pharmacol Biochem Behav       Date:  2010-04-18       Impact factor: 3.533

9.  Dopamine D1 and D2 antagonist effects on response likelihood and duration.

Authors:  Won Yung Choi; Cecile Morvan; Peter D Balsam; Jon C Horvitz
Journal:  Behav Neurosci       Date:  2009-12       Impact factor: 1.912

Review 10.  A "good parent" function of dopamine: transient modulation of learning and performance during early stages of training.

Authors:  Jon C Horvitz; Won Yung Choi; Cecile Morvan; Yaniv Eyny; Peter D Balsam
Journal:  Ann N Y Acad Sci       Date:  2007-03-14       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.